Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$206.39 - $268.73 $9.27 Million - $12.1 Million
-44,914 Reduced 51.52%
42,269 $8.73 Million
Q1 2024

May 15, 2024

SELL
$203.52 - $273.43 $13.6 Million - $18.3 Million
-66,872 Reduced 43.41%
87,183 $23.6 Million
Q4 2023

Feb 14, 2024

BUY
$164.52 - $238.84 $7.3 Million - $10.6 Million
44,342 Added 40.42%
154,055 $36.4 Million
Q3 2023

Nov 14, 2023

BUY
$194.44 - $217.61 $19.2 Million - $21.4 Million
98,565 Added 884.15%
109,713 $21.5 Million
Q2 2023

Aug 14, 2023

BUY
$183.71 - $210.25 $614,142 - $702,865
3,343 Added 42.83%
11,148 $2.34 Million
Q1 2023

May 15, 2023

SELL
$191.89 - $259.92 $8.44 Million - $11.4 Million
-43,995 Reduced 84.93%
7,805 $1.58 Million
Q4 2022

Feb 14, 2023

BUY
$197.11 - $250.07 $10.2 Million - $13 Million
51,800 New
51,800 $11.3 Million
Q2 2022

Aug 15, 2022

BUY
$204.13 - $302.4 $8.21 Million - $12.2 Million
40,200 Added 316.54%
52,900 $11.3 Million
Q1 2022

May 16, 2022

SELL
$255.51 - $362.11 $10.5 Million - $14.9 Million
-41,100 Reduced 76.39%
12,700 $3.61 Million
Q4 2021

Feb 14, 2022

SELL
$351.38 - $448.68 $281,104 - $358,944
-800 Reduced 1.47%
53,800 $20.3 Million
Q3 2021

Nov 15, 2021

SELL
$372.64 - $458.3 $298,112 - $366,640
-800 Reduced 1.44%
54,600 $22.5 Million
Q2 2021

Aug 16, 2021

BUY
$294.17 - $371.65 $16.3 Million - $20.6 Million
55,400 New
55,400 $20.5 Million
Q1 2018

May 15, 2018

SELL
$98.19 - $115.2 $14.7 Million - $17.3 Million
-150,000 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$100.43 - $118.09 $5.02 Million - $5.9 Million
50,000 Added 50.0%
150,000 $16.4 Million
Q3 2017

Nov 14, 2017

BUY
$96.72 - $109.26 $9.67 Million - $10.9 Million
100,000
100,000 $10.8 Million

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.96B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.